image title

integrative Structural and Chemical Biology team (iSCB)

Centre de Recherche en Cancérologie de Marseille (CRCM)




Jeremy ARIEY-BONNET (doctorant)


Thématique de recherche générale en oncopédiatrie

Découverte et validation de nouvelles cibles thérapeutiques dans les cancers réfractaires (repositionnement de médicaments, génomique fonctionnelle)



Clinique : Pr Nicolas André (Hôpital de la Timone, Marseille) et Dr Shripad Banavali (Tata Memorial Hospital, Mumbai, India)

Fondamentale / translationnelle : Pr Dominique Figarella-Branger (Institut de Neurophysiopathologie, Marseille), Dr Mathias François (University of Queensland,

Brisbane, Australia) et Pr Maria Kavallaris (Children’s Cancer Institute, Sydney, Australia)



Étroite collaboration avec le service d’Hématologie / Oncologie Pédiatrique de l’hôpital de la Timone (Pr Nicolas André)



Pasquier E., Tuset M.P., Street J., Sinnappan S., MacKenzie K.L., Braguer D., Andre N. and Kavallaris M. (2013) Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis, 16 (2): 373-86. (IF 4.4; 27 citations)

McGuire M.F., Enderling H., Wallace D.I., Batra J., Jordan M., Kumar S., Panetta J.C., Pasquier E.* (2013) Formalizing an integrative, multidisciplinary cancer therapy discovery workflow. Cancer Research, 73 (20): 6111-7. (IF 9.1; 11 citations) – corresponding author

Faivre C., Barbolosi D., Pasquier E. and Andre N. (2013) A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens. Cancer Chemotherapy and Pharmacology, 71 (4): 1013-9. (IF 2.8; 13 citations)

Yee E.M.H., Pasquier E., Iskander G., Wood K., Black D.S. and Kumar N. (2013) Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents. Bioorganic and Medicinal Chemistry, 21 (7): 1652-60. (IF 2.9; 13 citations)

Pasquier E.*, Street J., Pouchy C., Carre M., Gifford A.J., Murray J., Norris M., Trahair T., Andre N. and Kavallaris M. (2013) Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma. British Journal of Cancer, 108 (12): 2485-94. (IF 5.9; 59 citations) – corresponding author

Traore F., Togo B., Pasquier E., Dembélé A. and André N. (2013) Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02. Indian Journal of Cancer, 50 (3): 250-3. (IF 0.7; 6 citations)

André N., Banavali S., Snihur Y. and Pasquier E. (2013) Has the time come for metronomics in low-income and middle-income countries? Lancet Oncology, 14 (6): e239-48. (IF 36.4; 67 citations) – review article

Brandl M.B., Pasquier E., Li F., Beck D., Zhang S., Zhao H., Kavallaris M. and Wong S.T. (2014) Computational analysis of image-based drug profiling predicts synergistic drug

combinations: applications in triple-negative breast cancer. Molecular Oncology, 8 (8): 1548-60. (IF 5.3; 6 citations)

André N., Carré M. and Pasquier E.* (2014) Metronomics: towards personalized chemotherapy? Nature Reviews Clinical Oncology, 11 (7): 413-31. (IF 24.7; 118 citations) – review article , corresponding author

Banavali S., Pasquier E. and André N. (2015) Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma. Ecancermedicalscience, 9:499. (no IF yet; 16 citations)

Pasquier E., Tuset M.P., Sinnappan S., Carnell M., Macmillan A. and Kavallaris M. (2015) γ-Actin plays a key role in endothelial cell motility and neovessel maintenance. Vascular Cell, 6 (7): 2. (no IF yet; 9 citations)

André N., Cointe S., Barlogis V., Arnaud L., Lacroix R., Pasquier E., Dignat-George F., Michel G. and Sabatier F. (2015) Maintenance chemotherapy exerts metronomic-like antiangiogenic effects in children with ALL. Oncotarget, 6 (26): 23008-14. (IF 5.2; 9 citations)

Benzekry S., Pasquier E., Barbolosi D., Lacarelle B., Barlési F., André N. and Ciccolini J. (2015) Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. Seminars Cancer Biology, 35: 53-61. (IF 10.2; 16 citations) – review article

Heng M.A., Padovani L., Dory-Lautrec P., Gentet J.C., Verschuur A., Pasquier E., Figarella-Branger D., Scavarda D. and André N. (2016) Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma? Cancer Medicine, 5: 1542-1545. (IF 3.2; 5 citations)

Pasquier E.*, André N., Street J., Chougule A., Rekhi B., Ghosh J., Philip D.S., Meurer M., MacKenzie K.L., Kavallaris M. and Banavali S. (2016) Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine, 6: 87-95. (IF 6.2; 21 citations) – corresponding author

Le Grand M., Berges R., Pasquier E., Montero M.P., Borge L., Carrier A., Vasseur S., Bourgarel V., Buric D., André N., Braguer D., Carré M. (2017) Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression. Scientific Reports, 7 : 45136. (IF 4.1)

Ciccolini J., Barbolosi D., Meille C., Lombard A., Serdjebi C., Giacometti S., Padovani L., Pasquier E.*, André N. (2017) Pharmacokinetics and pharmacodynamics-based mathematical modeling identifies an optimal protocol for metronomic chemotherapy. Cancer Research, 77 : 4723-4733. (IF 9.1; 2 citations) – corresponding autho